Cornerstone Capital’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.33M | Sell |
85,470
-1,430
| -2% | -$46.2K | 0.3% | 50 |
|
|
2026
Q1 | $2.83M | Buy |
86,900
+64,350
| +285% | +$2.07M | 0.28% | 47 |
|
|
2025
Q4 | $793K | Hold |
22,550
| – | – | 0.08% | 69 |
|
|
2025
Q3 | $593K | Sell |
22,550
-1,730
| -7% | -$51.6K | 0.06% | 71 |
|
|
2025
Q2 | $643K | Hold |
24,280
| – | – | 0.07% | 66 |
|
|
2025
Q1 | $586K | Sell |
24,280
-520
| -2% | -$16.4K | 0.06% | 69 |
|
|
2024
Q4 | $998K | Sell |
24,800
-4,970
| -17% | -$283K | 0.11% | 62 |
|
|
2024
Q3 | $1.88M | Sell |
29,770
-4,180
| -12% | -$245K | 0.18% | 56 |
|
|
2024
Q2 | $1.8M | Hold |
33,950
| – | – | 0.18% | 53 |
|
|
2024
Q1 | $2.78M | Sell |
33,950
-76,025
| -69% | -$3.38M | 0.29% | 50 |
|
|
2023
Q4 | $2.05M | Sell |
109,975
-170
| -0.2% | -$2.22K | 0.22% | 48 |
|
|
2023
Q3 | $1.22M | Hold |
110,145
| – | – | 0.15% | 53 |
|
|
2023
Q2 | $1.79M | Sell |
110,145
-44,510
| -29% | -$933K | 0.21% | 48 |
|
|
2023
Q1 | $2.58M | Buy |
154,655
+15,300
| +11% | +$158K | 0.31% | 48 |
|
|
2022
Q4 | $1.31M | Sell |
139,355
-4,625
| -3% | -$20.6K | 0.17% | 50 |
|
|
2022
Q3 | $392K | Buy |
143,980
+4,840
| +3% | +$15.9K | 0.06% | 68 |
|
|
2022
Q2 | $402K | Buy |
139,140
+4,095
| +3% | +$10.1K | 0.05% | 69 |
|
|
2022
Q1 | $405K | Buy |
135,045
+12,825
| +10% | +$46K | 0.05% | 69 |
|
|
2021
Q4 | $562K | Hold |
122,220
| – | – | 0.06% | 66 |
|
|
2021
Q3 | $768K | Sell |
122,220
-12,400
| -9% | -$76.6K | 0.09% | 63 |
|
|
2021
Q2 | $806K | Buy |
134,620
+975
| +0.7% | +$5.79K | 0.09% | 61 |
|
|
2021
Q1 | $845K | Buy |
133,645
+5,180
| +4% | +$36.4K | 0.1% | 60 |
|
|
2020
Q4 | $723K | Buy |
128,465
+3,000
| +2% | +$18.2K | 0.09% | 57 |
|
|
2020
Q3 | $730K | Buy |
125,465
+10,852
| +9% | +$74.7K | 0.11% | 48 |
|
|
2020
Q2 | $826K | Buy |
114,613
+2,838
| +3% | +$18.8K | 0.14% | 43 |
|
|
2020
Q1 | $523K | Sell |
111,775
-134,021
| -55% | -$824K | 0.11% | 46 |
|
|
2019
Q4 | $1.97M | Sell |
245,796
-2,329
| -0.9% | -$17K | 0.28% | 46 |
|
|
2019
Q3 | $1.71M | Sell |
248,125
-1,000
| -0.4% | -$7.43K | 0.27% | 44 |
|
|
2019
Q2 | $2.07M | Buy |
249,125
+4,325
| +2% | +$37K | 0.32% | 44 |
|
|
2019
Q1 | $2.43M | Buy |
244,800
+32,200
| +15% | +$270K | 0.4% | 41 |
|
|
2018
Q4 | $1.63M | Buy |
212,600
+32,479
| +18% | +$388K | 0.29% | 49 |
|
|
2018
Q3 | $3.14M | Buy |
180,121
+34,621
| +24% | +$412K | 0.48% | 41 |
|
|
2018
Q2 | $1.38M | Buy |
145,500
+58,850
| +68% | +$391K | 0.23% | 45 |
|
|
2018
Q1 | $379K | Hold |
86,650
| – | – | 0.06% | 66 |
|
|
2017
Q4 | $352K | Buy |
+86,650
| New | +$252K | 0.06% | 69 |
|
Other funds holding VKTX
Cornerstone Capital's VKTX Position: Q2 2026 in Review
Cornerstone Capital reduced its Viking Therapeutics (VKTX) stake by 1.6% in Q2 2026, selling an estimated $46.2K and leaving 85,470 shares worth $3.33M. The position accounts for 0.3% of the portfolio, ranked #50.
Cornerstone Capital first reported a position in VKTX in Q4 2017 and has held it in 35 quarters since. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.
- Cornerstone Capital held 85,470 shares of Viking Therapeutics worth $3.33M as of Q2 2026.
- Cornerstone Capital sold 1,430 Viking Therapeutics shares in Q2 2026, an estimated $46.2K.
- Viking Therapeutics made up 0.3% of Cornerstone Capital's portfolio in Q2 2026, its #50 holding.
- Cornerstone Capital first reported a position in Viking Therapeutics in Q4 2017 and has held it in 35 quarters since.
- 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.
Based on Cornerstone Capital's 13F filing for Q2 2026, filed 3 Aug 2026.